Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Benefits of Peginterferon alfa-2b + TDF/TAF in Chronic Hepatitis B
NCT06707922Enrolling by invitation
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Mar 2022
- Primary completion
- May 2029
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (3 cohorts), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: The incidence of Hepatocellular Carcinoma (HCC), The incidence all-cause mortality and 2 more. Started Mar 2022; status: enrolling by invitation.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06707922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707922.